Latest Conference Articles

No Increased Blood-Related Side Effects With Radium-223 in Prostate Cancer

No Increased Blood-Related Side Effects With Radium-223 in Prostate Cancer

January 27th 2024, 8:00pm

ASCO Genitourinary Symposium

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.

Keytruda Plus Cabometyx Produces Responses in Cisplatin-Ineligible Bladder Cancer

Keytruda Plus Cabometyx Produces Responses in Cisplatin-Ineligible Bladder Cancer

January 27th 2024, 6:00pm

ASCO Genitourinary Symposium

Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.

Nubeqa, Hormone Therapy May Reduce Hospitalizations in Prostate Cancer

Nubeqa, Hormone Therapy May Reduce Hospitalizations in Prostate Cancer

January 27th 2024, 2:00pm

ASCO Genitourinary Symposium

Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.

Many Patients Miss Out on Testing to Guide Prostate Cancer Treatment

Many Patients Miss Out on Testing to Guide Prostate Cancer Treatment

January 26th 2024, 10:00pm

ASCO Genitourinary Symposium

Approximately 40% of patients with metastatic castration-resistant prostate cancer did not undergo certain types of tests that can be instrumental in treatment decisions.

Prostate Cancer Outcomes Improve With Zytiga, Prednisone, Erleada

Prostate Cancer Outcomes Improve With Zytiga, Prednisone, Erleada

January 26th 2024, 8:00pm

ASCO Genitourinary Symposium

Treatment with Zytiga, prednisone and Erleada plus another treatment regimen improved prostate cancer outcomes and did not change health-related quality of life outcomes.

Lynparza Plus Zytiga Boosts PFS, Response Rates in Metastatic Prostate Cancer

Lynparza Plus Zytiga Boosts PFS, Response Rates in Metastatic Prostate Cancer

January 26th 2024, 2:00pm

ASCO Genitourinary Symposium

Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.

Cabometyx, Tecentriq Combo Improves Time to Progression in mCRPC

Cabometyx, Tecentriq Combo Improves Time to Progression in mCRPC

January 25th 2024, 10:00pm

ASCO Genitourinary Symposium

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

An Oncologist Explains How She Uses ctDNA in Gastric Cancer

An Oncologist Explains How She Uses ctDNA in Gastric Cancer

January 24th 2024, 10:00pm

ASCO Gastrointestinal Cancers Symposium

Circulating tumor DNA can be a valuable tool in gastric cancer, but unanswered questions remain, an expert said.

Step Count Gives Insight to GI Cancer Outcomes in Older Patients

Step Count Gives Insight to GI Cancer Outcomes in Older Patients

January 23rd 2024, 11:00pm

ASCO Gastrointestinal Cancers Symposium

Older adults with gastric cancer tended to have better outcomes when they walked 2,500 steps per day or more.

Fruzaqla Delays Colorectal Cancer Progression, Prolongs Patient Survival

Fruzaqla Delays Colorectal Cancer Progression, Prolongs Patient Survival

January 23rd 2024, 10:00pm

ASCO Gastrointestinal Cancers Symposium

Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.